ArticleClinical pharmacokinetics2023

Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn's Disease and Ulcerative Colitis.

Ana Victoria Ponce-Bobadilla et al.PubMed ↗Publisher ↗

No numbers read from the abstract.